Brandon Capital

👏 👏 👏 to the Vaxxas team on announcing The National Institutes of Health's licensing of your DS2 vaccine antigen candidate for use in RSV prophylactic vaccines. 🌍 Why It Matters: Respiratory Syncytial Virus (RSV) leads to an estimated 33 million acute respiratory infections annually. 💡 Innovative Delivery: Vaxxas' cutting-edge needle-free technology utilises a patch with thousands of microprojections to deliver the vaccine directly to immune cells, simplifying administration and eliminating the need for refrigeration. 🚀 Next Steps: After completing pre-clinical development, Vaxxas is set to progress to Phase I clinical trials. Vaxxas CEO David Hoey, "Published preclinical results show the potential immunogenic advantages of this antigen candidate as the basis for an RSV vaccine that will provide robust and durable protection. "These potential advantages, coupled with the potential of the Vaxxas needle-free technology to eliminate the need for refrigerated distribution and enable self-administration, could offer a vaccine that significantly impacts how we protect populations against this serious respiratory infection in the future." We're proud to support Vaxxas as they drive pioneering solutions in public health. Read more in @AuManufacturing news and media 👇🏿 https://lnkd.in/gKU-X7Sc #BrandonCapital #Biotech #RSVVaccine #InnovationInHealth #ClinicalTrials

🚀 PolyActiva Showcases Clinical Data at Eyecelerator and AusBiotech Invest PolyActiva is pioneering the development of ocular implants for sustained drug delivery, targeting glaucoma—the second most common cause of irreversible blindness. 🔹 PA5108 demonstrated clinically meaningful IOP reductions between 26% and 35% over 48 weeks. 🔹94% of participants did not require additional drop therapy during treatment. 🔹To date, the PA5108 implant has been found to be safe and generally well tolerated by trial participants. 🔹Scaling manufacturing capabilities to support the commencement of late-stage clinical trials in early 2025, with trials to be conducted under an IND submission to the FDA. “With our proprietary biodegradable polymer implant, we’re not only improving treatment adherence but also setting the stage for therapies that could address other ocular diseases.”  Vanessa Waddell, PolyActiva CEO. 🚀 What’s Next? PolyActiva is preparing for a Phase 2b clinical trial of PA5108, with plans to commence late-stage trials in early 2025 under an IND submission to the FDA. Thanks to Insight Ophthalmic News for covering the story 👇🏾 https://lnkd.in/g2rRtTXg #PolyActiva #Biotech #OcularHealth #Glaucoma #Innovation #ClinicalTrials #Healthcare

Aravax Completes Recruitment in Phase 2 Study of PVX108 - Novel Immunotherapy for Peanut Allergy Their advanced immunotherapy candidate, PVX108, which is designed to retrain the immune system by delivering engineered peptides that precisely target T cells, could potentially reverse the course of allergic disease. 🔹The study: Conducted across 14 sites in the U.S. and Australia, the trial enrolled 95 patients, ages 4-17, to assess PVX108's safety and effectiveness over one year. 🔹Looking ahead Results are expected in H1 2026. Aravax CEO Dr Pascal Hickey, “The timely completion of recruitment across multiple sites in the U.S. and Australia, is a significant step for Aravax. There remains a critical need for better treatments for serious food allergies. PVX108 has been designed to provide a safe and convenient treatment that can potentially reverse the course of allergic disease. We look forward to continuing evaluation of PVX108 efficacy in this potentially Phase 3-enabling study.” 👏👏👏 to the Aravax team, led by Pascal! We’re proud to support your vision to transform allergy management. https://lnkd.in/eCCwUA5K #BrandonCapital #Biotech #PeanutAllergy #Immunotherapy #ClinicalTrials

MEET US IN STOCKHOLM - Our CEO Professor Darren Kelly Kelly will be in Europe 2-9 November, attending Informa Connect EBD Group #Bioeurope2024.   He is open for meetings with investors, pharma and industry partners to discuss the next stage of our development as we plan for our Phase IIb trials of our novel #GPR68 inhibitor #asengeprast (#FT011).   Asengeprast is a first in class GPR68 proton sensing antagonist (a switch regulating #fibrosis via modulating both anti-fibrotic and anti-inflammatory activity). Certa has successfully completed Phase IIa clinical trial with asengeprast for the treatment of Systemic Sclerosis (#SSc), #scleroderma.   We have a wider pipeline of small molecule candidate drugs that target GPR68, each designed to address different fibrotic indications for example kidney disease (FSGS, DKD, CKD).   Get in touch via the partnering system to meet up or email dkelly@certatherapeutics.com to meet up in Stockholm or London.   #fibrosis #drugdevelopment #clinicaltrial #scleroderma #kidneydisease

🚀Interested in applying for CUREator+ Round Two? Then, join the Brandon BioCatalyst CUREator and ANDHealth teams at an Information Session next week. 📅Monday, 28 October ⏰ 12 pm to 1 pm 📹 Via Zoom Register to secure your spot👇🏽 https://lnkd.in/gZ72n845 Supported by funding from the Medical Research Future Fund (MRFF), CUREator+ offers up to $5 million in non-dilutive funding to support breakthrough biomedtech innovations with clinical and commercial potential. 📝Applications close Wednesday, 4th December, at 12:00 pm (AEDT); further details can be found on our website. https://lnkd.in/g45fjDA7

🚀 Calling on forward-thinking organisations in tech, engineering, manufacturing, healthcare, agtech, biotech, energy, mining…and more! 🚀 Are you ready to drive real change in the diversity of C-suites and boardrooms across Australia’s STEM industries? Join us in shaping the future of leadership by hosting a WILD Board X Observer! WILD Board X is your opportunity to: ✅ Demonstrate genuine commitment to diversity and inclusion. ✅ Access fresh perspectives and insights from exceptional, board-ready female STEM leaders. ✅ Strengthen your succession planning and innovation strategy. By hosting a custom-matched Board X Observer, you'll be part of an immersive 12-month board observership program that empowers talented female leaders while enhancing your board’s strategic edge. Proudly supported by the Department of Industry, Science and Resources, the Board X program is designed to create lasting impact for both observers and participating boards. Join our growing community of Host Boards to create a future of more diverse and innovative STEM leadership for Australia. 🌟 🔗 Interested in joining this movement? Contact anna@wildforstem.com to learn more. Transport Accident Commission (TAC) Murdoch Children's Research Institute (MCRI) Medicines Australia Brandon Capital ANDHealth Australian Academy of Technological Sciences & Engineering National Breast Cancer Foundation (NBCF) Canopus Currus Biologics Pty Ltd Vaxxas Additive Assurance Nourish Ingredients Pollinate Group ElectraLith GlyTherix Ltd MTPConnect #WILDforSTEM #BoardX #DiversityInSTEM #STEMLeadership #Innovation #FutureofSTEM #Inclusion #WomenInLeadership #STEMWomen #BoardLeadership

📢Next week, some of the Brandon Capital team will dive into current and emerging trends alongside local and international biotech leaders at the AusBiotech 2024 Life Sciences Conference. 🎤 Bob Soh - Biotech in 2024: The trends, the opportunities, and what investors are looking for. 🎤 Melissa McBurnie - ESG Reporting: What do investors really want to see and how to get started. 🎤 Michael Bettess - Considerations when investing in early-stage university spin-outs. 📅 Wednesday 30 October to Friday 1 November 📍 Melbourne Convention & Exhibition Centre ☕ From interstate and looking for coffee? Paper Tiger at 10 Queen St is a team favourite and a lovely 20-minute walk across the river from the MECC. The full program is below, and we're looking forward to catching up with you all at the sessions, charging stations, and coffee carts! https://lnkd.in/eP4P3vJA 🌏 #AusBiotech2024 #Biotech #LifeSciences #Innovation #Investment

🌍Congratulations to Brandon Capital portfolio company George Medicines, whose successful Phase III Clinical Trial data has appeared in The Lancet, the Journal of the American Medical Association and the American College of Cardiology over the last few weeks. George Medicines is developing an innovative therapy to address hypertension, one of the world’s most pressing health challenges. 📊 1.2 billion people affected globally ⚠️ Only half receive adequate treatment 💡 There’s a critical need for more effective solutions Abstracts covering results from their Phase III clinical trials from The Lancet, JAMA, Journal of the American Medical Association and the American College of Cardiology 👇🏾 𝗧𝗵𝗲 𝗟𝗮𝗻𝗰𝗲𝘁 Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. https://lnkd.in/ggubSRAG 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗶𝗼𝗻 (𝗝𝗔𝗠𝗔) Is a Low-Dose Triple-Drug Combination Pill Protocol the Answer for Hypertension Control in Sub-Saharan Africa? https://lnkd.in/gB3r47Kn 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗖𝗼𝗹𝗹𝗲𝗴𝗲 𝗼𝗳 𝗖𝗮𝗿𝗱𝗶𝗼𝗹𝗼𝗴𝘆 Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension https://lnkd.in/gC55MN4P Based on research developed by Brandon BioCatalyst Member The George Institute for Global Health, we couldn't be more thrilled for the entire George team, including Anthony Rodgers and Mark Mallon, as well as our Brandon Capital Managing Partner Stephen Thompson!

🚀 Did you know the Frontier Health and Medical Research initiative will deliver $700 million to researchers developing new health and medical breakthroughs over the next ten years? 🖥️ The Australian Government Department of Health and Aged Care is hosting a webinar that will cover the initiative's goals, application process, key requirements, and an update on experiences so far. Register 👇🏽

📢 CUREator+ Opens Second Funding Round! 🚀 In partnership with Brandon BioCatalyst and ANDHealth, CUREator+ offers up to $5 million per project in non-dilutive funding for companies pioneering innovative health solutions. Funded by the Australian Federal Government's Medical Research Future Fund (#mrff), this program aims to support the development of: 💡 Therapeutics 🔬 Diagnostics 🦾 Medical and connected devices 📱 Digital health technologies Applications are now open to entrepreneurial researchers, clinical innovators, and founders across Australia. Visit https://lnkd.in/g45fjDA7 to: 📧Schedule time with a CUREator or ANDHealth Analyst 📹Register to attend the webinar  🚀Access the link to submit your Expression of Interest (EOI) EOIs close at 12 pm (AEDT) on December 4, 2024. #Innovation #Healthcare #BrandonCapital #CUREator #MedicalResearch #Biotech #DigitalHealth #Funding #ClinicalResearch